PD-1/PD-L1抑制剂在结直肠癌治疗中的机制研究进展
Research progress on the mechanism of PD-1/PD-L1 inhibitors in the treatment of colorectal cancer
张傲 1李清波 1王栋 1张艳 1徐靖宣 1孔宪斌 1孟静岩1
作者信息
- 1. 天津中医药大学中医学院,天津 301617
- 折叠
摘要
免疫治疗在肿瘤治疗中占据着重要地位,已知 T细胞表面的程序性死亡受体-1(programmed death receptor-1,PD-1)与肿瘤细胞上的 PD-1 配体 1(PD-1 ligand 1,PD-L1)结合可以阻止 T细胞对肿瘤细胞的免疫杀伤作用,促进肿瘤细胞的免疫逃逸.本文围绕 PD-1/PD-L1 抑制剂介绍了其在结直肠癌治疗中存在的问题,结直肠癌中 PI3K/AKT、JAK/STAT、MAPK、NF-κB 等信号通路与PD-1/PD-L1 的相互作用机制,进一步探讨了 PD-1/PD-L1 抑制剂与肠道微生物、化疗、放疗、靶向和天然化合物的治疗研究.
Abstract
Immunotherapy plays an important role in tumor treatment.It is known that the programmed death receptor-1(PD-1)on the surface of T cells binds to the PD-1 ligand 1(PD-L1)on tumor cells,which can prevent the immune killing effect of T cells on tumor cells and promote immune escape of tumor cells.This paper introduced the problems of PD-1/PD-L1 inhibitors in colorectal cancer treatment,the interaction mechanism of signaling pathways such as PI3K/AKT,JAK/STAT,MAPK and NF-κB with PD-1/PD-L1 in colorectal cancer,and further discussed the thera-peutic studies of PD-1/PD-L1 inhibitors with gut microbes,chemotherapy,radiotherapy,targeted and natural com-pounds.
关键词
PD-1/PD-L1/信号通路/结直肠癌/联合治疗/天然化合物Key words
PD-1/PD-L1/Signaling pathway/Colorectal cancer/Combination therapy/Natural compounds引用本文复制引用
基金项目
国家自然科学基金资助项目(81973728)
国家自然科学基金青年基金项目(82204962)
天津市自然科学基金项目(22JCQNJC00490)
天津市教委科研计划项目(2021KJ134)
出版年
2024
NETL
NSTL
万方数据